Compare BLTE & SYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | SYM |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.2B |
| IPO Year | 2021 | 2021 |
| Metric | BLTE | SYM |
|---|---|---|
| Price | $163.68 | $43.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 17 |
| Target Price | ★ $228.89 | $62.86 |
| AVG Volume (30 Days) | 168.4K | ★ 1.3M |
| Earning Date | 11-09-2026 | 08-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $2,246,922,000.00 |
| Revenue This Year | N/A | $24.67 |
| Revenue Next Year | N/A | $29.40 |
| P/E Ratio | ★ N/A | $349.04 |
| Revenue Growth | N/A | ★ 25.65 |
| 52 Week Low | $72.65 | $37.68 |
| 52 Week High | $200.00 | $87.88 |
| Indicator | BLTE | SYM |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 48.82 |
| Support Level | $167.28 | $39.15 |
| Resistance Level | $172.02 | $44.73 |
| Average True Range (ATR) | 5.28 | 1.57 |
| MACD | -0.86 | -0.17 |
| Stochastic Oscillator | 39.80 | 34.76 |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Symbotic Inc. is an automation technology company that develops solutions to improve operating efficiencies in modern warehouses. The group designs, commercializes, and deploys end-to-end technology systems that significantly enhance supply chain operations. The company automates the processing of pallets, cases, and individual items within warehouse environments. Its systems strengthen operations at the front end of the supply chain and provide benefits to all supply partners downstream. The company operates in two geographical regions: the United States and international markets, with the majority of its revenue generated in the United States.